Affiliations: [a] Shanghai Key Laboratory of Molecular Imaging, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China
| [b] School of Pharmacy, Shanghai University of Medicine & Health Sciences, Shanghai, China
| [c] School of Health Sciences and Engineering, University of Shanghai for Science and Technology, Shanghai, China
| [d] Center for Disease Control and Prevention of Harbin, Harbin, China
Correspondence:
[*]
Correspondence to: Xuefeng Gu, Shanghai University of Medicine and Health Sciences, 279 Zhouzhu Rd, Pudong New District, Shanghai 201318, China. Tel.: +86 021 65883903; E-mail: guxf@sumhs.edu.cn and Yuhui Pan, Center for Disease Control and Prevention of Harbin, 30 Weixing Rd, Daowai District, Harbin 150056, China. Tel.: +86 0451 57672096; E-mail: yuhuipan@126.com.
Note: [1] These authors contributed equally to this work.
Abstract: Alzheimer’s disease (AD) involves degeneration of cells in the brain. Due to insidious onset and slow progression, AD is often not diagnosed until it gets progressed to a more severe stage. The diagnosis and treatment of AD has been a challenge. In recent years, high-throughput sequencing technologies have exhibited advantages in exploring the pathogenesis of diseases. However, the types of cells of the central nervous system are complex and traditional bulk sequencing cannot reflect their heterogeneity. Single-cell sequencing technology enables study at the individual cell level and has an irreplaceable advantage in the study of complex diseases. In recent years, this field has expanded rapidly and several types of single-cell sequencing technologies have emerged, including transcriptomics, epigenomics, genomics and proteomics. This review article provides an overview of these single-cell sequencing technologies and their application in AD.
